Medicamen Biotech share price
NSE: MEDICAMEQBSE: 531146Pharmaceuticals & BiotechnologySmall Cap
Last close ₹253.35down ₹11.80 (4.45%)BSE ₹253.75
Share price at the NSE close on 23 Oct 2026. Previous close ₹265.15.
52-week range of traded prices to 23 Oct 2026
₹212.40Low, 29 Jun 2026₹447.65High, 25 Nov 2025
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹344 Cr1,991st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 27 May 2026
- 1.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.39%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- 3.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 27 May 2026
- 0.17
- Volume, NSEVolume. Shares traded on the last trading day.
- 20,122
Results
Standalone, as consolidated accounts are on record for only 7 of the last ten years; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 14 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹44 Crdown 19.80%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹2.53 Crdown 14.98%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 5.8%
Revenue by year
Peak revenue ₹179 Cr, year to Mar 2026
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 15 Nov | Dec 2024Filed 11 Feb | Mar 2025Filed 13 Jun | Jun 2025Filed 12 Aug | Sep 2025Filed 14 Nov | Dec 2025Filed 13 Feb | Mar 2026Filed 27 May | Jun 2026Filed 14 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 42.8 | 41.1 | 26.0 | 38.4 | 42.2 | 43.5 | 54.7 | 43.9 |
| Net profit | 2.3 | 2.5 | 2.4 | 1.6 | 2.2 | 2.6 | 3.0 | 2.5 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 5.3% | 6.1% | 9.3% | 4.3% | 5.2% | 6.0% | 5.4% | 5.8% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMACEUTICALS, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: a results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement.PE ratio and valuation history
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 4% of 1,751 trading days since Nov 2018.
LowestHighest
Its median4.3Industry median2.9
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.18.5
At or below today's level on 6% of 1,091 trading days over the last 5 years.
LowestHighest
Its median34.2Industry median18.7
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 97% of 2,479 trading days over the last 10 years.
LowestHighest
Its median0.00%Industry median0.53%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −53.0% | −6.7% | −50.1% | 0.4% |
| 3 years | −30.0% | −16.8% | −16.2% | 0.3% |
| 5 years | −15.8% | −7.4% | −9.2% | 0.2% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual funds holding it
2 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 1
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 1
| Fund | |||
|---|---|---|---|
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 212 | 0.02% | ₹69,000 |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 100 | 0.02% | ₹33,000 |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Medicamen Biotech in market cap. 1 company in the table last traded before then: its row is priced on its last trade.
Medicamen Biotech is not on the chart: it has no P/E or return on equity today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Haleos LabsHALEOSLABS | 453 | 28.7 | 2.1 | 13.7 | −3.1% | −8.5% | 7.7% | 7.4% | 0.10% |
 Infinium PharmachemINFINIUM | 446 | 36.7 | 3.7 | – | +21.8% | +41.8% | 10.5% | – | 0.00% |
 Albert DavidALBERTDAVD | 436 | 19.3 | 1.1 | 16.1 | +11.4% | +258.5% | 5.8% | 4.1% | 0.65% |
 Jenburkt PharmaceuticalsJENBURPH | 384 | 11.7 | 2.0 | 8.1 | +9.1% | +1.2% | 17.8% | 19.2% | 2.38% |
 Aarey Drugs & PharmaceuticalsAAREYDRUGS | 340 | – | – | – | −7.7% | – | – | 1.8% | 0.00% |
 Astonea LabsASTONEALAB | 340 | 75.2 | 5.9 | – | – | – | 12.0% | – | 0.00% |
 Lyka LabsLYKALABS | 293 | – | 3.2 | – | −2.6% | – | −9.2% | −8.0% | 0.00% |
 Astal LaboratoriesASTALLTD | 279 | 28.7 | 0.9 | 19.3 | +122.7% | +4.4% | 5.4% | 4.2% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.Highest ₹1.00 a share, in 5 years, the latest the year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 18 Sep 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.00 |
| 19 Sep 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.00 |
| 19 Sep 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.00 |
| 20 Sep 2023 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.00 |
| 19 Sep 2022 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
30 Sep · Trading Plan under PIT
Aug 2026
Medicamen Biotech share price by year
Each calendar year to 2025.Medicamen Biotech share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 364.65 | −28.8% | 551.95 | 295.35 |
| 2024 | 512.45 | −15.0% | 604.55 | 369.35 |
| 2023 | 603.15 | −27.4% | 866.70 | 555.90 |
| 2022 | 830.50 | −6.4% | 1,201.40 | 567.85 |
| 2021BSE close | 887.60 | +86.6% | 988.70 | 435.10 |
| 2020BSE close | 475.75 | +39.3% | 506.30 | 171.65 |
| 2019BSE close | 341.50 | −21.2% | 548.65 | 299.80 |
| 2018BSE close | 433.40 | −30.2% | 749.10 | 401.15 |
| 2017BSE close | 620.80 | +115.5% | 668.10 | 309.20 |
| 2016BSE close | 288.05 | +369.1% | 341.90 | 38.85 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 265.15 | 265.15 | 251.90 | 253.35 | 255.29 | 20,122 |
| 22 Oct 2026 | 262.00 | 271.85 | 259.40 | 265.15 | 265.76 | 9,869 |
| 21 Oct 2026 | 272.00 | 272.90 | 259.00 | 264.55 | 266.32 | 25,883 |
| 19 Oct 2026 | 279.95 | 284.35 | 270.50 | 272.00 | 275.00 | 36,836 |
| 16 Oct 2026 | 297.00 | 299.00 | 280.15 | 284.45 | 284.26 | 24,971 |
| 15 Oct 2026 | 304.75 | 304.75 | 293.60 | 294.60 | 297.74 | 8,288 |
| 14 Oct 2026 | 301.90 | 304.00 | 293.05 | 295.85 | 297.22 | 5,873 |
| 13 Oct 2026 | 300.00 | 306.00 | 290.05 | 298.55 | 296.08 | 11,474 |
| 12 Oct 2026 | 305.00 | 307.00 | 297.15 | 299.45 | 301.78 | 6,166 |
| 9 Oct 2026 | 304.00 | 305.00 | 298.00 | 300.85 | 301.22 | 11,443 |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Medicamen Biotech Limited
- NSE symbol
- MEDICAMEQ
- BSE code
- 531146
- ISIN
- INE646B01010
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Oct 1995 on BSE, Oct 2021 on NSE
- Face value
- ₹10
- CIN
- L74899DL1993PLC056594
- Corporate identity number, the registrar of companies' code for it